Please use this identifier to cite or link to this item: http://nopr.niscpr.res.in/handle/123456789/27796
Full metadata record
DC FieldValueLanguage
dc.contributor.authorNair, Gopakumar G-
dc.contributor.authorFernandes, Andreya-
dc.contributor.authorNair, Karthika-
dc.date.accessioned2014-04-07T10:37:22Z-
dc.date.available2014-04-07T10:37:22Z-
dc.date.issued2014-03-
dc.identifier.issn0975-1076 (Online); 0971-7544 (Print)-
dc.identifier.urihttp://hdl.handle.net/123456789/27796-
dc.description79-88en_US
dc.description.abstractIn a short span of less than 10 years after the new WTO/TRIPS based product patent regime came into effect, there have been many landmark judgments from Indian Courts on interpretation of various provisions of the exhaustive (Indian) Patents Act, 1970, as amended. Even though very large number of product patents have been granted during this period, patent challenges and infringement suits are limited to a few blockbuster molecules. Currently, litigations are in progress, including those in appeals as well as on matters remanded back to patent office. The landmark cases, in recent times, are dealt with, herein. Additional areas which may require judicial intervention arising out of the ambiguities in the Act and Rules are also briefly dealt with.en_US
dc.language.isoen_USen_US
dc.publisherNISCAIR-CSIR, Indiaen_US
dc.rights CC Attribution-Noncommercial-No Derivative Works 2.5 Indiaen_US
dc.sourceJIPR Vol.19(2) [March 2014]en_US
dc.subjectGleevecen_US
dc.subjectSection 3(d)en_US
dc.subjectSupreme Court orderen_US
dc.subjectIPABen_US
dc.subjectErlotiniben_US
dc.subjectSitagliptinen_US
dc.subjectSorafeniben_US
dc.subjectDasatiniben_US
dc.subjectSunitiniben_US
dc.subjectDate of patenten_US
dc.titleLandmark Pharma Patent Jurisprudence in Indiaen_US
dc.typeArticleen_US
Appears in Collections:JIPR Vol.19(2) [March 2014]

Files in This Item:
File Description SizeFormat 
JIPR 19(2) 79-88.pdf95.78 kBAdobe PDFView/Open


Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.